๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Surgery in malignant pancreatic neuroendocrine tumors

โœ Scribed by Scott Q. Nguyen; Luz P. Angel; Celia M. Divino; Stefanie Schluender; Richard R.P. Warner


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
113 KB
Volume
96
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Background

Because of their rarity and indolent nature, optimal management of malignant pancreatic neuroendocrine tumors remains controversial. The purpose of this study is to review a series of patients with these tumors and investigate the role of surgery in the treatment.

Methods

A retrospective study of 73 patients (ages 24โ€“86 years; 36 women) undergoing treatment at a tertiary academic medical center was performed. Patient demographics, diagnostic tests, operations, pathologic findings, adjuvant treatments, and survival were reviewed.

Results

Seventyโ€four percent of patients had advanced disease with hepatic metastases and 30% had functional tumors. Fiftyโ€seven percent of the patients underwent pancreatic resections. Two 60โ€day mortalities occurred and the postoperative complication rate was 27%. Overall 5โ€year survival rate was 44%. There was no difference in survival between patients with functional and nonfunctional tumors. Patients undergoing resection, even in metastatic disease, had better survival than patients who had no resection (60% vs. 30%, Pโ€‰=โ€‰0.025). Recurrence occurred in 20% of patients who underwent a curative resection.

Conclusion

Patients with malignant pancreatic neuroendocrine tumors commonly present with advanced disease. Although, curative resection is not frequent, survival benefit may be obtainable with aggressive surgical management even in the face of metastatic disease. J. Surg. Oncol. 2007;96:397โ€“403. ยฉ 2007 Wileyโ€Liss, Inc.


๐Ÿ“œ SIMILAR VOLUMES


Liver embolizations of patients with mal
โœ B. K. Eriksson; E. G. Larsson; B. M. Skogseid; A. M. Lรถfberg; L. E. Lรถrelius; K. ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 96 KB ๐Ÿ‘ 2 views

## BACKGROUND. Patients with neuroendocrine gastrointestinal tumors usually present with inoperable metastatic disease and severe hormonal symptoms. Specific chemotherapy, interferon-โฃ (IFN), and somatostatin analogs are established therapies for these patients, but all of them eventually fail. Hep

Molecular characteristics and predictors
โœ Christian N. Arnold; Takeshi Nagasaka; Ajay Goel; Iris Scharf; Patricia Grabowsk ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 219 KB

## Abstract To better understand the molecular pathogenesis of neuroendocrine tumors (NET), we investigated the molecular and clinical characteristics of malignant poorly differentiated colorectal NET and compared these findings with sporadic CRC and wellโ€differentiated benign and malignant foreโ€/m

Neuroendocrine differentiation in prosta
โœ P. Anthony di Sant'Agnese; Abraham T. K. Cockett ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 456 KB ๐Ÿ‘ 2 views

## BACKGROUND. The prostatic neuroendocrine cell is a regulatory cell that produces serotonin and peptide hormones. This cell is part of a more widely dispersed diffuse neuroendocrine regulatory system known as the APIJD system. Focal neuruendocrine differentiation is seen in virtually all prostat